Wang, Eric S.
Verano, Alyssa L.
Nowak, Radosław P.
Yuan, J. Christine
Donovan, Katherine A. http://orcid.org/0000-0002-8539-5106
Eleuteri, Nicholas A.
Yue, Hong http://orcid.org/0000-0003-4347-3193
Ngo, Kenneth H. http://orcid.org/0000-0001-5511-2825
Lizotte, Patrick H.
Gokhale, Prafulla C.
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Fischer, Eric S. http://orcid.org/0000-0001-7337-6306
Funding for this research was provided by:
Damon Runyon Cancer Research Foundation (DRG-2270-16, DRR-50-18)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA214608)
Article History
Received: 27 October 2020
Accepted: 19 April 2021
First Online: 25 May 2021
Competing interests
: N.S.G. is an equity holder and scientific advisor for Syros, Soltego (board member), C4, B2S, Petra, Allorion, Inception and Jengu. E.S.F. is an equity holder and scientific advisor for C4 Therapeutics, Jengu (board member), Neomorph and Civetta Therapeutics and is a consultant to Novartis, Sanofi, AbbVie, Pfizer, Astellas, EcoR1 capital and Deerfield. The Fischer lab receives or has received research funding from Novartis, Ajax and Astellas not related to this work. E.S.W., A.L.V., R.P.N., J.C.Y., K.A.D., N.S.G. and E.S.F. are inventors on a patent covering the compounds described in this paper.